FRANKFURT (Reuters) - German researchers have found that COVID-19 therapies developed by Eli Lilly and Regeneron lose most of their effectiveness when exposed in laboratory tests to the Omicron ...

Add Yahoo as a preferred source to see more of our stories on Google. People would like to know whether their COVID-19 vaccine is protective enough or a previous infection will keep them safe. Experts ...

Last week, Adagio Therapeutics raised $80 million in a series B financing to speed its COVID-19 antibody into development. This week, it provided some details about how its approach differs from the ...

Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back ...

WASHINGTON — At the height of the coronavirus lockdown, President Donald Trump and his top health advisers trumpeted a new test that would help Americans reclaim their lives — one that would tell them ...

FRANKFURT, Dec 14 (Reuters) - German researchers have found that COVID-19 therapies developed by Eli Lilly (LLY.N), opens new tab and Regeneron (REGN.O), opens new tab lose most of their effectiveness ...